Most Recent Additions*

 

Smart Spine Implants.
Rory K. Murphy

 

Use of Pressure Transducers.
Rafael Ortega, Christopher Connor, Faina Kotova, Wu Deng, and Christopher Lacerra

 

United States (US) multi-center study to assess the validity and reliability of the Spinal Cord Independence Measure (SCIM III).
K D Anderson, M E Acuff, B G Arp, D Backus, S Chun, K Fisher, J E Fjerstad, D E Graves, K Greenwald, S L Groah, S J Harkema, J A Horton, M-N Huang, M Jennings, K S Kelley, S M Kessler, S Kirshblum, S Koltenuk, M Linke, I Ljungberg, J Nagy, L Nicolini, M J Roach, S Salles, W M Scelza, M S Read, R K Reeves, M D Scott, K E Tansey, J L Theis, C Z Tolfo, M Whitney, C D Williams, C M Winter, and J M Zanca

 

Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Zifan Zhou, Robert Urman, Karminder Gill, Andrew S Park, Fiston Vuvu, Leah B Patel, Jingsong Lu, Rolin L Wade, Lindsay Frerichs, and Mark E Bensink

 

Galcanezumab for the prevention of migraine.
Lindsay M Frerichs and Deborah I Friedman

 

Odor representations from the two nostrils are temporally segregated in human piriform cortex.
Gulce Nazli Dikecligil, Andrew I Yang, Nisha Sanghani, Timothy Lucas, H Isaac Chen, Kathryn A Davis, and Jay A Gottfried

 

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Yen-Hwa Chang, Jaroslav Hajek, Stefan N Symeonides, Jae Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B Haas, Piotr Sawrycki, Howard Gurney, Christine Chevreau, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, John M Burke, Gurjyot Doshi, Delphine Topart, Stephane Oudard, Hans Hammers, Hiroshi Kitamura, Jens Bedke, Rodolfo F Perini, Pingye Zhang, Kentaro Imai, Jaqueline Willemann-Rogerio, David I Quinn, Thomas Powles, and Rob Galamaga

 

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Evgeny Kopyltsov, María J Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung-Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R Merchan, Eric Winquist, Pablo Maroto, Jeffrey C Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frederic Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E Dutcus, Alan D Smith, Lea Dutta, Kalgi Mody, Rodolfo F Perini, Dongyuan Xing, Toni K Choueiri, and Rob Galamaga

 

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke, Rafael Morales Barrera, Aude Fléchon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani, Evan Y Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, and Rob Galamaga

 

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Robert J Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Boris Alekseev, Sun Young Rha, Jaime Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung-Hoo Hong, Howard Gurney, María José Méndez-Vidal, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph Burgents, Cixin He, Chinyere E Okpara, Jodi McKenzie, Toni K Choueiri, and Rob Galamaga

Link

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study
Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane, Edward Arrowsmith, Todd M. Bauer, Rohit K. Jain, Bradley Somer, Elaine T. Lam, Mark D. Kochenderfer, Ana Molina, Gurjyot Doshi, Brian Lingerfelt, Ralph J. Hauke, Vijay Gunuganti, Ian Schnadig, Peter Van Veldhuizen, Mark Fleming, Robert Galamaga, Mukul Gupta, Hugo Hool, Thomas Hutson, Joshua Zhang, M Brent McHenry, Jennifer L. Johansen, and Scott S. Tykodi

Link

Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era
Adam M. Petrich, Irene B. Helenowski, Locke J. Bryan, Shaina A. Rozell, Robert Galamaga, and Chadi Nabhan

Link

ε4 is associated with younger age at ischemic stroke onset but not with stroke outcome
Cecilia Lagging, Erik Lorentzen, Tara M. Stanne, Annie Pedersen, Martin Söderholm, John W. Cole, Katarina Jood, Robin Lemmens, Chia-Ling Phuah, Natalia S. Rost, Vincent Thijs, Daniel Woo, Jane M. Maguire, Arne Lindgren, and Christina Jern

Link

White matter hyperintensity longitudinal morphometric analysis in association with Alzheimer disease
Jeremy Fuller Strain, Chia-Ling Phuah, Babatunde Adeyemo, Kathleen Cheng, Kyle B. Womack, John McCarthy, Manu Goyal, Yasheng Chen, Aristeidis Sotiras, Hongyu An, Chengjie Xiong, Andrea Scharf, Catherine Newsom-Stewart, John Carl Morris, Tammie Lee Benzinger, Jin-Moo Lee, and Beau M. Ances

Link

Vascular endothelial-cadherin as a marker of endothelial injury in preclinical Alzheimer disease
Rawan Tarawneh, Rachel S. Kasper, Jessie Sanford, Chia-Ling Phuah, Jason Hassenstab, and Carlos Cruchaga

*Updated as of 04/18/24.